Sansure Biotech Inc. (688289.SH) announced that its fully automated nucleic acid processing system (S-S13E-P/S-S13E-P1) has recently received EU CE-IVDR certification. The device enables end-to-end automation from sample to report, including tube decapping, pipetting, nucleic acid extraction, PCR setup, sealing, amplification, and result analysis. It features high efficiency, precision, intelligent control, and broad compatibility.

The system supports a wide range of tests, covering HPV, sexually transmitted diseases, bloodborne pathogens, respiratory infections, vector-borne diseases, and pharmacogenomics. It is adaptable to various professional settings such as laboratories, hospitals, and testing centers, efficiently meeting diverse needs for sample testing and experimental analysis within limited space.

This CE-IVDR certification marks a critical step in the company's internationalization and standardization of molecular diagnostic technologies. The milestone not only demonstrates the product's superior performance and safety standards but also reflects the company's commitment to leading industry innovation and serving global markets.

Moving forward, Sansure Biotech will continue to drive technological advancements and integrated solutions, empowering global healthcare institutions and public health systems to build a more efficient, precise, and reliable health protection ecosystem.